Capital for 7TM
Hørsholm - 7TM Pharma A/S has raised $7.6 million in the recent completion of its third round of venture capital financing in October, bringing the total capital raised to $42 million. Investors in the current round include Index Ventures (Switzerland), Alta Partners (USA), Novo A/S (Denmark) and Dansk Innovationsinvestering (Denmark). “This third round of financing provides the necessary financial muscle to mature our pipeline and move our first proprietary compound into clinical development,” declared Mette Kirstine Agger, Chief Executive Officer of 7TM Pharma. The drug discovery and development company focuses on medicines acting through 7TM receptors - targeted by one quarter of all prescription drugs -, and has recently initiated pre-clinical development of its first anti-obesity therapeutic compound.